Effects of an HMG-CoA reductase inhibitor in combination with an ACE inhibitor or angiotensin II type 1 receptor antagonist on myocardial metabolism in ischemic rabbit hearts.

摘要: We investigated the effects of a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, pravastatin, an angiotensin converting enzyme (ACE) temocaprilat, and II type 1 (AT1) receptor antagonist, CV-11974, on myocardial metabolism during ischemia in isolated rabbit hearts using phosphorus 31-nuclear magnetic resonance (31P-NMR) imaging. Forty-five minutes continuous normothermic global was carried out. Pravastatin, CV-11974 or nitric oxide synthase L-NAME administered from 60 min prior to ischemia. Japanese white rabbits were divided into following experimental groups, control group (n=7), treated with pravastatin (P group; n=7), temocaprilat (P+T (P+CV (P+L-NAME n=7). During ischemia, P group, as well either P+T P+CV showed significant inhibition decreases adenosine triphosphate (ATP) intracellular pH (pHi) (p<0.01, respectively, at end compared P+L-NAME group), increase inorganic phosphate (Pi) group). These results suggest that significantly improved energy This beneficial effect dependent NO synthase. However, this not enhanced by CV-11974.